2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Tuberous Sclerosis: new trials by email Literature Review of Tuberous Sclerosis trials Research Report on Tuberous Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy Ganaxolone - Tuberous Sclerosis Complex | Phase 3 | Terminated | Marinus Pharmaceuticals | 117 | 2022-05-16 | 2025-10-01 |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures GWP42003-P - Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome | Phase 3 | Terminated | Jazz Pharmaceuticals | 3 | 2021-05-19 | 2025-10-31 |
Epilepsies, Myoclonic (1) · Epilepsy (1) · Lennox Gastaut Syndrome (1) · Seizures (1) · Spasms, Infantile (1) · Tuberous Sclerosis 1 (1) · Tuberous Sclerosis 2 (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hamartoma (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Neoplasms (2) · Neoplasms, Multiple Primary (2) · Neoplastic Syndromes, Hereditary (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurocutaneous Syndromes (2) · Neurodegenerative Diseases (2) · Brain Diseases (1)
Cannabidiol (1) · ganaxolone (1)
Jazz Pharmaceuticals (1) · Marinus Pharmaceuticals (1)
Italy (2) · Spain (2) · United States (2) · Australia (1) · Canada (1) · China (1) · France (1) · Germany (1) · Israel (1) · United Kingdom (1)